This clinical trial is focused on studying the long-term safety of a treatment called AV-101 for people with Pulmonary Arterial Hypertension (PAH). PAH is a condition where the blood pressure in the arteries of the lungs is higher than normal, which can lead to heart problems. The treatment being tested, AV-101, contains an active substance known as imatinib, which is a type of medication called a tyrosine kinase inhibitor. This medication is administered through inhalation using a device called a dry powder inhaler.
The purpose of this study is to ensure that AV-101 is safe for long-term use in individuals who have already completed a previous study involving this treatment. Participants will continue to use AV-101 and will be monitored for any side effects or changes in their condition. The study will also look at how AV-101 affects certain health measures, such as the distance a person can walk in six minutes, levels of a heart-related protein called NT-proBNP, and heart function as seen in an ultrasound test called a cardiac echo.
Throughout the study, participants will receive regular check-ups to assess their health and the effects of the treatment. The study aims to provide valuable information on the safety and potential benefits of AV-101 for people living with PAH. This research is important for understanding how this treatment can help manage the condition over a longer period.



Austria
Belgium
Czechia
France
Germany
Greece
Ireland
Italy
Latvia
Poland
Portugal
Spain
Sweden
The Netherlands